Do analysts prefer CPIX or LLY?

Eli Lilly and Company has a consensus price target of $1,283.64, indicating a potential upside of 11.69%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Eli Lilly and Company 1 Sell rating(s) 4 Hold rating(s) 24 Buy rating(s) 2 Strong Buy rating(s) 2.87

Does the media prefer CPIX or LLY?

In the previous week, Eli Lilly and Company had 107 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 109 mentions for Eli Lilly and Company and 2 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.90 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Eli Lilly and Company is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eli Lilly and Company 59 Very Positive mention(s) 20 Positive mention(s) 19 Neutral mention(s) 6 Negative mention(s) 4 Very Negative mention(s) Positive

Do analysts rate CPIX or JNJ?

Johnson & Johnson has a consensus price target of $266.39, indicating a potential upside of 3.85%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Johnson & Johnson 0 Sell rating(s) 6 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.80

Does the media prefer CPIX or JNJ?

In the previous week, Johnson & Johnson had 114 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 116 mentions for Johnson & Johnson and 2 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 0.80 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 67 Very Positive mention(s) 15 Positive mention(s) 21 Neutral mention(s) 7 Negative mention(s) 3 Very Negative mention(s) Positive

Do analysts recommend ABBV or CPIX?

AbbVie currently has a consensus target price of $269.29, indicating a potential upside of 7.14%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AbbVie 0 Sell rating(s) 6 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 2.84 Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ABBV or CPIX?

In the previous week, AbbVie had 88 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 90 mentions for AbbVie and 2 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 0.85 beat Cumberland Pharmaceuticals' score of -0.33 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 44 Very Positive mention(s) 11 Positive mention(s) 21 Neutral mention(s) 7 Negative mention(s) 2 Very Negative mention(s) Positive Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend CPIX or MRK?

Merck & Co., Inc. has a consensus target price of $134.50, suggesting a potential upside of 3.07%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Merck & Co., Inc. 0 Sell rating(s) 7 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.65

Does the media prefer CPIX or MRK?

In the previous week, Merck & Co., Inc. had 62 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 2 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.11 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Merck & Co., Inc. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Merck & Co., Inc. 43 Very Positive mention(s) 4 Positive mention(s) 10 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts rate CPIX or PFE?

Pfizer has a consensus target price of $28.50, indicating a potential upside of 13.55%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cumberland Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pfizer 2 Sell rating(s) 14 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.19

Does the media prefer CPIX or PFE?

In the previous week, Pfizer had 64 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 66 mentions for Pfizer and 2 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.77 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cumberland Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 36 Very Positive mention(s) 8 Positive mention(s) 16 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Positive

Cumberland Pharmaceuticals (CPIX) Competitors

$6.68 0.00 (0.00%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$6.76 +0.08 (+1.12%)

As of 07/31/2026 07:56 PM Eastern

Compare

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

Should you buy Cumberland Pharmaceuticals stock or one of its competitors? MarketBeat compares Cumberland Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cumberland Pharmaceuticals include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Pfizer (PFE). These companies are all part of the "pharmaceuticals" industry.

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Eli Lilly and Company (NYSE:LLY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Eli Lilly and Company has a consensus price target of $1,283.64, indicating a potential upside of 11.69%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts clearly believe Eli Lilly and Company is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eli Lilly and Company	1 Sell rating(s)	4 Hold rating(s)	24 Buy rating(s)	2 Strong Buy rating(s)	2.87

Cumberland Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market.

Eli Lilly and Company has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.49	N/A
Eli Lilly and Company	$65.18B	16.61	$20.64B	$28.15	40.83

Eli Lilly and Company has a net margin of 34.98% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Eli Lilly and Company's return on equity of 105.77% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Eli Lilly and Company	34.98%	105.77%	23.76%

In the previous week, Eli Lilly and Company had 107 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 109 mentions for Eli Lilly and Company and 2 mentions for Cumberland Pharmaceuticals. Eli Lilly and Company's average media sentiment score of 0.90 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eli Lilly and Company	59 Very Positive mention(s)	20 Positive mention(s)	19 Neutral mention(s)	6 Negative mention(s)	4 Very Negative mention(s)	Positive

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Eli Lilly and Company beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Johnson & Johnson (NYSE:JNJ) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

In the previous week, Johnson & Johnson had 114 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 116 mentions for Johnson & Johnson and 2 mentions for Cumberland Pharmaceuticals. Johnson & Johnson's average media sentiment score of 0.80 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	67 Very Positive mention(s)	15 Positive mention(s)	21 Neutral mention(s)	7 Negative mention(s)	3 Very Negative mention(s)	Positive

Johnson & Johnson has a consensus price target of $266.39, indicating a potential upside of 3.85%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts clearly believe Johnson & Johnson is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Johnson & Johnson shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Johnson & Johnson has a net margin of 21.48% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Johnson & Johnson's return on equity of 32.42% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Johnson & Johnson	21.48%	32.42%	13.35%

Johnson & Johnson has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.49	N/A
Johnson & Johnson	$94.19B	6.56	$26.80B	$8.63	29.72

Summary

Johnson & Johnson beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to AbbVie?

AbbVie (NYSE:ABBV) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

AbbVie has a net margin of 9.80% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Cumberland Pharmaceuticals' return on equity of -12.01% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-466.39%	14.35%
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%

AbbVie currently has a consensus target price of $269.29, indicating a potential upside of 7.14%. Given AbbVie's stronger consensus rating and higher probable upside, equities research analysts plainly believe AbbVie is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	6 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.84
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, AbbVie had 88 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 90 mentions for AbbVie and 2 mentions for Cumberland Pharmaceuticals. AbbVie's average media sentiment score of 0.85 beat Cumberland Pharmaceuticals' score of -0.33 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	44 Very Positive mention(s)	11 Positive mention(s)	21 Neutral mention(s)	7 Negative mention(s)	2 Very Negative mention(s)	Positive
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

AbbVie has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Cumberland Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

70.2% of AbbVie shares are held by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Comparatively, 42.1% of Cumberland Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AbbVie has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$61.16B	7.26	$4.23B	$3.54	71.00
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.49	N/A

Summary

AbbVie beats Cumberland Pharmaceuticals on 15 of the 17 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Merck & Co., Inc. (NYSE:MRK) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Merck & Co., Inc. has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.49	N/A
Merck & Co., Inc.	$65.01B	4.96	$18.25B	$3.55	36.76

In the previous week, Merck & Co., Inc. had 62 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 64 mentions for Merck & Co., Inc. and 2 mentions for Cumberland Pharmaceuticals. Merck & Co., Inc.'s average media sentiment score of 1.11 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Merck & Co., Inc. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Merck & Co., Inc.	43 Very Positive mention(s)	4 Positive mention(s)	10 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Cumberland Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market. Comparatively, Merck & Co., Inc. has a beta of 0.19, meaning that its share price is 81% less volatile than the broader market.

Merck & Co., Inc. has a consensus target price of $134.50, suggesting a potential upside of 3.07%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.65

15.5% of Cumberland Pharmaceuticals shares are held by institutional investors. Comparatively, 76.1% of Merck & Co., Inc. shares are held by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are held by company insiders. Comparatively, 0.2% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Merck & Co., Inc. has a net margin of 13.59% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Merck & Co., Inc.'s return on equity of 27.55% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Merck & Co., Inc.	13.59%	27.55%	10.73%

Summary

Merck & Co., Inc. beats Cumberland Pharmaceuticals on 15 of the 16 factors compared between the two stocks.

How does Cumberland Pharmaceuticals compare to Pfizer?

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Pfizer (NYSE:PFE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Pfizer shares are owned by institutional investors. 42.1% of Cumberland Pharmaceuticals shares are owned by company insiders. Comparatively, 0.6% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cumberland Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Pfizer has a net margin of 11.83% compared to Cumberland Pharmaceuticals' net margin of -17.60%. Pfizer's return on equity of 19.44% beat Cumberland Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cumberland Pharmaceuticals	-17.60%	-12.01%	-4.24%
Pfizer	11.83%	19.44%	8.41%

In the previous week, Pfizer had 64 more articles in the media than Cumberland Pharmaceuticals. MarketBeat recorded 66 mentions for Pfizer and 2 mentions for Cumberland Pharmaceuticals. Pfizer's average media sentiment score of 0.77 beat Cumberland Pharmaceuticals' score of -0.33 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cumberland Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	36 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	3 Negative mention(s)	2 Very Negative mention(s)	Positive

Pfizer has a consensus target price of $28.50, indicating a potential upside of 13.55%. Given Pfizer's stronger consensus rating and higher possible upside, analysts plainly believe Pfizer is more favorable than Cumberland Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cumberland Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19

Pfizer has higher revenue and earnings than Cumberland Pharmaceuticals. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cumberland Pharmaceuticals	$44.52M	2.25	-$2.84M	-$0.49	N/A
Pfizer	$62.58B	2.29	$7.77B	$1.31	19.16

Summary

Pfizer beats Cumberland Pharmaceuticals on 16 of the 17 factors compared between the two stocks.

Get Cumberland Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPIX vs. The Competition

Export

Metric	Cumberland Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$100.07M	$11.71B	$6.86B	$12.42B
Dividend Yield	N/A	2.72%	2.59%	10.03%
P/E Ratio	-13.63	799.05	282.30	24.66
Price / Sales	2.25	751.29	564.98	76.51
Price / Cash	18.22	14.82	28.60	46.71
Price / Book	4.07	10.36	10.92	6.07
Net Income	-$2.84M	$2.82B	$3.49B	$347.99M
7 Day Performance	-4.98%	-0.13%	-0.64%	-0.44%
1 Month Performance	4.87%	-3.99%	-5.24%	-4.81%
1 Year Performance	89.77%	156.16%	61.98%	18.61%

Cumberland Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPIX Cumberland Pharmaceuticals	0.3855 of 5 stars	$6.68 flat	N/A	+89.8%	$100.07M	$44.52M	N/A	80	Upcoming Earnings
LLY Eli Lilly and Company	4.3684 of 5 stars	$1,222.81 +0.2%	$1,283.64 +5.0%	+50.9%	$1.15T	$72.25B	43.47	50,000	Trending News Upcoming Earnings
JNJ Johnson & Johnson	4.4678 of 5 stars	$268.16 +0.5%	$265.30 -1.1%	+53.3%	$646.30B	$97.93B	31.08	138,200	Trending News Analyst Downgrade
ABBV AbbVie	4.575 of 5 stars	$266.96 +1.4%	$269.29 +0.9%	+28.8%	$471.81B	$61.16B	131.55	57,000	Trending News Earnings Report
MRK Merck & Co., Inc.	4.6887 of 5 stars	$131.92 +0.1%	$134.50 +2.0%	+64.6%	$325.73B	$65.01B	37.15	75,000	Trending News Upcoming Earnings Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CPIX) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cumberland Pharmaceuticals (CPIX) Competitors

CPIX vs. LLY, JNJ, ABBV, MRK, and PFE

How does Cumberland Pharmaceuticals compare to Eli Lilly and Company?

Do analysts prefer CPIX or LLY?

Which has more risk & volatility, CPIX or LLY?

Which has preferable valuation & earnings, CPIX or LLY?

Is CPIX or LLY more profitable?

Does the media prefer CPIX or LLY?

Do institutionals and insiders believe in CPIX or LLY?

Summary

How does Cumberland Pharmaceuticals compare to Johnson & Johnson?

Which has more risk & volatility, CPIX or JNJ?

Does the media prefer CPIX or JNJ?

Do analysts rate CPIX or JNJ?

Do insiders and institutionals have more ownership in CPIX or JNJ?

Is CPIX or JNJ more profitable?

Which has stronger earnings & valuation, CPIX or JNJ?

Summary

How does Cumberland Pharmaceuticals compare to AbbVie?

Is ABBV or CPIX more profitable?

Do analysts recommend ABBV or CPIX?

Does the media favor ABBV or CPIX?

Which has more risk and volatility, ABBV or CPIX?

Do insiders & institutionals have more ownership in ABBV or CPIX?

Which has preferable valuation & earnings, ABBV or CPIX?

Summary

How does Cumberland Pharmaceuticals compare to Merck & Co., Inc.?

Which has preferable valuation & earnings, CPIX or MRK?

Does the media prefer CPIX or MRK?

Which has more risk & volatility, CPIX or MRK?

Do analysts recommend CPIX or MRK?

Do insiders and institutionals believe in CPIX or MRK?

Is CPIX or MRK more profitable?

Summary

How does Cumberland Pharmaceuticals compare to Pfizer?

Do insiders and institutionals have more ownership in CPIX or PFE?

Which has more volatility & risk, CPIX or PFE?

Is CPIX or PFE more profitable?

Does the media prefer CPIX or PFE?

Do analysts rate CPIX or PFE?

Which has better valuation and earnings, CPIX or PFE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPIX vs. The Competition

Cumberland Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools